Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2016 | 1 |
2017 | 2 |
2018 | 3 |
2019 | 1 |
2021 | 1 |
2022 | 1 |
2024 | 0 |
Search Results
7 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
A catalogue of treatment and technologies for malignant pleural mesothelioma.
Expert Rev Anticancer Ther. 2016;16(4):455-63. doi: 10.1586/14737140.2016.1162100.
Expert Rev Anticancer Ther. 2016.
PMID: 26943000
Review.
Immune cells in mesothelioma microenvironment simplistic marker of response to nivolumab plus ipilimumab?
Disselhorst MJ, Lubeck Y, van der Noort V, Quispel-Janssen J, Seignette IM, Sanders J, Peters D, Hooijberg E, Baas P.
Disselhorst MJ, et al. Among authors: quispel janssen j.
Lung Cancer. 2022 Nov;173:49-52. doi: 10.1016/j.lungcan.2022.08.019. Epub 2022 Sep 5.
Lung Cancer. 2022.
PMID: 36122471
Item in Clipboard
Nose in malignant mesothelioma-Prediction of response to immune checkpoint inhibitor treatment.
Disselhorst MJ, de Vries R, Quispel-Janssen J, Wolf-Lansdorf M, Sterk PJ, Baas P.
Disselhorst MJ, et al. Among authors: quispel janssen j.
Eur J Cancer. 2021 Jul;152:60-67. doi: 10.1016/j.ejca.2021.04.024. Epub 2021 Jun 1.
Eur J Cancer. 2021.
PMID: 34087572
Item in Clipboard
Chemical Profiling of Primary Mesothelioma Cultures Defines Subtypes with Different Expression Profiles and Clinical Responses.
Schunselaar LM, Quispel-Janssen JMMF, Kim Y, Alifrangis C, Zwart W, Baas P, Neefjes J.
Schunselaar LM, et al. Among authors: quispel janssen jmmf.
Clin Cancer Res. 2018 Apr 1;24(7):1761-1770. doi: 10.1158/1078-0432.CCR-17-1345. Epub 2017 Oct 24.
Clin Cancer Res. 2018.
PMID: 29066506
Item in Clipboard
Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma.
Quispel-Janssen J, van der Noort V, de Vries JF, Zimmerman M, Lalezari F, Thunnissen E, Monkhorst K, Schouten R, Schunselaar L, Disselhorst M, Klomp H, Hartemink K, Burgers S, Buikhuisen W, Baas P.
Quispel-Janssen J, et al.
J Thorac Oncol. 2018 Oct;13(10):1569-1576. doi: 10.1016/j.jtho.2018.05.038. Epub 2018 Jun 14.
J Thorac Oncol. 2018.
PMID: 29908324
Free article.
Clinical Trial.
Item in Clipboard
Comprehensive Pharmacogenomic Profiling of Malignant Pleural Mesothelioma Identifies a Subgroup Sensitive to FGFR Inhibition.
Quispel-Janssen JM, Badhai J, Schunselaar L, Price S, Brammeld J, Iorio F, Kolluri K, Garnett M, Berns A, Baas P, McDermott U, Neefjes J, Alifrangis C.
Quispel-Janssen JM, et al.
Clin Cancer Res. 2018 Jan 1;24(1):84-94. doi: 10.1158/1078-0432.CCR-17-1172. Epub 2017 Oct 23.
Clin Cancer Res. 2018.
PMID: 29061644
Item in Clipboard
Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial.
Disselhorst MJ, Quispel-Janssen J, Lalezari F, Monkhorst K, de Vries JF, van der Noort V, Harms E, Burgers S, Baas P.
Disselhorst MJ, et al. Among authors: quispel janssen j.
Lancet Respir Med. 2019 Mar;7(3):260-270. doi: 10.1016/S2213-2600(18)30420-X. Epub 2019 Jan 16.
Lancet Respir Med. 2019.
PMID: 30660511
Clinical Trial.
Item in Clipboard
Cite
Cite